Effects of calcium channel blockers on antidepressant action of Alprazolam and Imipramine

Aburawi SM, Al-Tubuly RA, Alghzewi EA, Gorash ZM
Dept of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, El-Fateh University, Libya

Abstract: Alprazolam is effective as an anxiolytic and in the adjunct treatment of depression. In this study, the effects of calcium channel antagonists on the antidepressant action of alprazolam and imipramine were investigated. A forced swimming maze was used to study behavioral despair in albino mice. Mice were divided into nine groups (n = 7 per group). One group received a single dose of 1% Tween 80; two groups each received a single dose of the antidepressant alone (alprazolam or imipramine); two groups each received a single dose of the calcium channel blocker (nifedipine or verapamil); four groups each received a single dose of the calcium channel blocker followed by a single dose of the antidepressant (with same doses used for either in the previous four groups). Drug administration was performed concurrently on the nine groups. Our data confirmed the antidepressant action of alprazolam and imipramine. Both nifedipine and verapamil produced a significant antidepressant effect (delay the onset of immobility) when administered separately. Verapamil augmented the antidepressant effects of alprazolam and imipramine (additive antidepressant effect). This may be due to the possibility that verapamil might have antidepressant-like effect through different mechanism. Nifedipine and imipramine combined led to a delay in the onset of immobility greater than their single use but less than the sum of their independent administration. This may be due to the fact that nifedipine on its own might act as an antidepressant but blocks one imipramine mechanism that depends on L-type calcium channel activation. Combining nifedipine with alprazolam produced additional antidepressant effects, which indicates that they exert antidepressant effects through different mechanisms.

Introduction
Alprazolam is an anxiolytic agent used primarily for short-term relief of mild to moderate anxiety and nervous tension. It is effective in the treatment of depression and panic attacks. It has a high affinity for the GABA benzodiazepine receptor complex [1], and it is a full agonist for the GABA_A receptor [2]. Imipramine is a better tricyclic antidepressant than all other drugs in its category [3]. It prevents the reuptake of noradrenaline (NA) and 5-hydroxytryptamine (5-HT) at nerve terminals [4].

Calcium antagonists have been shown to affect many different physiological processes, in particular neurotransmitter release. Nifedipine mainly affects the heart and smooth muscle, causing inhibition of calcium entry associated with depolarization. Nifedipine is relatively muscle selective and acts as a vasodilator [1]. It is a highly specific antagonist of the L-type channel blocks [5]. Verapamil is relatively cardioselective with an antidysrhythmic action. Verapamil is effective in the treatment of hypertension and angina [1]. Verapamil enhanced the antidepressant action of alprazolam (6); Verapamil as an inhibitor of the CYP 450 3A4 (7) may affect the imipramine (8) and alprazolam action, that are considered as substrates for CYP 450 3A4 (7) [1].

The forced swim test (FST) [9] is used as a rodent model of depression. The mouse FST model has been widely used in screening antidepressants because it is simple and has been reported to be reliable across laboratories. The mouse model is more sensitive than the rat model because it produces fewer false positives [10]. The FST is specific enough to discriminate between antidepressants, neuroleptics and anxiolytics [11]. It is based on the observation that when an animal is forced to swim in a situation from which there is no escape, it will first go through a period of vigorous activity and then cease to move, other than trying to keep its head above water. Immobility indicates a state of despair in which the mouse has learned that escape is impossible.

FST immobility is reduced by different treatments known to be effective in depression [12, 13]. There is a significant correlation between the potency of antidepressants in the FST and in clinical settings, but such a correlation has not been demonstrated in any other animal model of depression [12, 14]. In this model the circadian time cycle did not alter the duration of immobility of mice [15].

Behavioral despair is mediated by central catecholamines. Drugs that increase central transmission of dopamine or NA decrease immobility, whereas agents having the opposite effect increase immobility. The advantage of the mouse FST model is that it can readily test the possible mechanisms of antidepressant action by using specific agonists/antagonists. By augmenting or blocking antidepressant activity with agonist/antagonist receptor ligands, it is possible to detect which receptor is involved in the antidepressant effect [16].

In this study we used behavior despair models for mental depression to investigate the effect of the calcium channel blockers, nifedipine and verapamil, on the antidepressant action of alprazolam and imipramine. These two calcium channel blockers are used in the treatment of physical illnesses that may be concurrent with depression. Understanding the interaction between antidepressants and calcium channel...
blockers could indicate whether there is a need to modify antidepressant doses when coadministered with calcium channel blockers.

**Materials and methods**

Albino mice (25 - 40 g) were used. Groups of mice were housed in separate cages. The animals were housed at room temperature (20–25°C) and a 12-h dark/light cycle. Alprazolam was supplied by Upjohn Co. Ltd, Egypt, Imipramine by Novartis, AG, Switzerland, Nifedipine by Bayer, AG, Germany, and Verapamil by Weimer Phara Gmbh, Germany.

Because alprazolam is not freely soluble in saline, all the drugs were dissolved in 1% Tween 80 in distilled water [17]; they were injected intraperitoneally. Imipramine was given at 10 mg/kg and alprazolam at 5 mg/kg [18 and our unpublished results]. The doses of calcium channel blockers were chosen from previous studies [18-21].

Mice were divided into nine groups (n = 7 per group). One group received a single dose of 5ml/kg of 1% Tween 80; two groups each received a single dose of the antidepressant alone (alprazolam, 5mg/kg; imipramine, 10mg/kg); two groups each received a single dose of the calcium channel blocker (nifedipine, 5mg/kg; verapamil, 10mg/kg); four groups each received a single dose of the calcium channel blocker followed by a single dose of the antidepressant (with same doses used for either in the previous four groups). Drug administration was performed concurrently on the nine groups. For all groups, the time of onset of immobility was measured 60 min after drug administration.

We used a behavioral model of immobility first postulated by Porsolt [22] and Porsolt et al. and named the behavioral despair model [23]. In this model, mice are forced to swim in a restricted space from which there is no escape. Following an initial period of vigorous activity, the mice adopt a characteristic immobile posture with no further attempt to escape, and this reflects a state of despair or lowered mood. Mice were forced to swim for four minutes in a vertical glass cylinder (height=27 cm, diameter=16.5 cm) containing fresh tap water at 27°C and a depth of 15 cm [24]. Mice were forced to swim only once.

**Statistical analysis**

SPSS 8 software was used to determine whether the observed data were normally distributed using Kolmogrov Smirnov maximum deviation test for goodness of fit. If the data were normally distributed, one-way ANOVA was applied, followed by Post Hoc test to compare between groups. If the data were not normally distributed, groups were compared using Mann-Whitney two samples (non–matched) $U$ test. The difference was considered to be significant at $p \leq 0.05$.

**Results**

**Effects of nifedipine on the onset of immobility**

Administration of imipramine, alprazolam, or nifedipine separately produced a significant delay in the onset of immobility compared to the control group. The combined administration of alprazolam and nifedipine produced a significant delay in the onset of immobility compared to either alprazolam treated mice or the control group. The effect of imipramine on the onset of immobility (delay) was potentiated by the administration of nifedipine (Table 1).

Table 1: Effects of nifedipine on the onset of immobility by alprazolam and imipramine using the behavior despair model of depression. The values are expressed as mean ± S.E.M. a: $p \leq 0.05$ compared to control group treated with Tween 80-treated. b: $p \leq 0.05$ compared to group treated with alprazolam + nifedipine. c: $p \leq 0.05$ compared to group treated with imipramine + nifedipine.

| Treatment (n = 7) | Onset of immobility (sec) |
|------------------|--------------------------|
| Tween 80         | 40.5 ± 0.99              |
| Alprazolam (5 mg/kg) | 59.8 ± 1.16            |
|                  | a, b                     |
| Alprazolam (5mg/kg) + Nifedipine (5 mg/kg) | 72.1 ± 1.18           |
|                  | a                        |
| Imipramine (10 mg/kg) | 77.1 ± 0.83           |
|                  | a, c                     |
| Imipramine (10 mg/kg) + Nifedipine (5 mg/kg) | 83.4 ± 1.04           |
|                  | a                        |
| Nifedipine (5 mg/kg) | 60.1 ± 1.48            |
|                  | a, b, c                  |

**Effects of verapamil on the onset of immobility**

Administration of verapamil, alprazolam or imipramine produced a significant delay in the onset of immobility compared to the control group. Coadministration of verapamil augmented the effects of imipramine. Similarly, coadministration of verapamil augmented the effects of alprazolam. Our findings demonstrate that verapamil significantly delays the onset of immobility produced by alprazolam (Table 2).

**Discussion**
It has been suggested that calcium channel inhibitors may have antidepressant properties, and that calcium may play an important role in affective disorders [25]. Voltage-dependent calcium channel antagonists have been reported to produce antidepressant-like effects in rodents [26-28]. Interruption of the Ca²⁺-calmodulin-NOS-guanylyl cyclase subcellular signaling pathway at any point produces antidepressant-like effects [26].

Table 2: Effects of verapamil on the onset of immobility produced by alprazolam or imipramine using the behavior despair model of depression. The values are expressed as mean ± S.E.M. a: p ≤ 0.05 compared to control group treated with Tween 80-treated. b: p ≤ 0.05 compared to group treated with alprazolam + verapamil. c: p ≤ 0.05 compared to the group treated with imipramine + verapamil.

| Treatment (n = 7) | Onset of immobility (sec) |
|------------------|---------------------------|
| Tween 80         | 40.5 ± 0.99               |
| Alprazolam (5 mg/kg) | 59.8 ± 1.16              |
| Alprazolam (5 mg/kg)+ Verapamil (10 mg/kg) | 82.8 ± 0.73          |
| Imipramine (10 mg/kg) | 77.1 ± 0.83             |
| Imipramine (10 mg/kg) + Verapamil (10 mg/kg) | 93.5 ± 1.13          |
| Verapamil (10 mg/Kg) | 57.4 ± 0.61             |

In our study, nifedipine delayed the onset of immobility in the forced swimming maze. This antidepressant action could have been mediated by 5-HT₁A activation [29], whereby nifedipine reduced 5-HT uptake [30]. This would lead to an increase in the cytosolic calcium activity via 5-HT₂ receptors [31]. Serotonin may activate calcium influx through calcium channels by activation of 5-HT receptors, which are insensitive to nifedipine [32], in neuronal cells. The increase in calcium influx is through 5-HT₃ receptors [31, 33], the 5-HT₃ receptor being a ligand-gated ion channel activated by the neurotransmitter serotonin. Receptors of this subtype have been localized to several regions of the brain, they appear to be involved in many neuronal functions [34], and to mediate antidepressant effects [35]. In glial cells, the increase in intracellular calcium is through 5-HT₂ receptors [31]. It has been suggested that the pharmacology of L-type Ca²⁺-channel blockers overlaps with that of 5-HT₂ receptor antagonists [36].

Nifedipine may produce an antidepressant action through GABA-A activation [37], which leads to the release of NA that produces an antidepressant effect [38]. This may be GABA acting on second inhibitory interneurons (as in direct and indirect pathways of extrapyramidal systems). Nifedipine may also produce its antidepressant effect by increasing the release of intracellular calcium through GABA receptors [37] and NA [39, 40]. The central antidepressant effect of nifedipine may be mediated through an interaction, with novel modulatory sites on GABA receptors, that is not through picrotoxin, flumazenil or Zn²⁺ sites [37].

Nifedipine may exert an antidepressant action by decreasing the ability of vesicles to re-uptake NA [41]. Nifedipine may block calcium uptake through potential operated (K⁺) channels or through receptor operated (5-HT) channels [42].

Moreover, verapamil showed an antidepressant-like effect as it delayed the onset of immobility in the swimming maze. Studies have shown that verapamil modulates the action of antidepressant drugs that downregulate β adrenergic systems [43]. It has a similar final effect as β blockers, and shares this effect with antidepressant drugs [44]. Working on different types of calcium entry, verapamil blocks the prejunctional α₂ receptors, which leads to an increase in NA release [45-48]. Verapamil may have direct catecholamine-releasing effects, as it interacts with catecholamine storage vesicles in a way that reduces their ability to take up and store catecholamine, and thereby increasing NA release from sympathetic nerves [41]. Verapamil has no effect on NA-induced increase in calcium influx, which means that there are verapamil-sensitive and verapamil-insensitive calcium channels [49]. Verapamil enhances ATP response [50], which is released along with NA from the motor nerves; ATP may indeed be a co-transmitter [51, 52]. Allgaier et al. suggested that ATP induces NA release from sympathetic neurons via its action on a subcell of the nicotinic cholinoreceptor, because this effect was blocked by nicotinic receptor antagonists [53]. NA produces depolarization by decreasing the membrane permeability to K⁺ ions. It also increases calcium influx to the cells via calcium channel-activated NA receptors and potential-dependent slow calcium-channels activated by NA-induced membrane depolarization [54]. NA stimulates calcium chloride conductance, leading to opening of voltage-gated calcium channels [55].

Verapamil inhibits 5-HT uptake by a mechanism that does not involve alteration in calcium fluxes [56], which leads to enhancement of 5-HT release.
Serotonin activates 5-HT₁A receptors to increase endogenous 5-HT, which is competitively inhibited by imipramine. Serotonin activates 5-HT₃ presynaptic receptors, inducing calcium influx, which triggers the release of calcium from intracellular stores and leads to increased calcium in both the cytoplasm and nucleus. Activating 5-HT₃ postsynaptic receptors induces depolarization. Thus both mechanisms would result in an antidepressant action.

Serotonin may regulate GABA neurotransmission through 5-HT₃ receptors. It also increases chloride channel activity by acting on the 5-HT₁C receptor. It has been suggested that the increased [Ca²⁺], activates chloride channels (Cl⁻), causing an efflux of chloride and subsequent depolarization of the cell membrane; this leads to the opening of voltage-gated calcium channels. Currents can be activated separately by Ca²⁺ release from intracellular stores (in response to external application of caffeine or NA) and by Ca²⁺ influx through voltage-dependent Ca²⁺ channels. Activation of Cl⁻ channels by Ca²⁺ release produces a membrane depolarization that is required for an enhanced opening of voltage-dependent Ca²⁺ channels in response to noradrenaline in venous smooth muscle. It was concluded that extracellular chloride is essential for contraction in afferent arterioles after activation of voltage-dependent calcium channels.

Verapamil cannot modify calcium-dependent fractions of GABA release induced by high K⁺ depolarization. Presynaptic action of Zn in the hippocampus increases the release of GABA in the synaptic cleft. This Zn effect is not affected by verapamil. Zinc enhances GABA release by potentiating AMPA/Kainate receptors in the hippocampus region, followed by a decrease in presynaptic glutamate release. Zinc is considered an inhibitory neuromodulator of glutamate. The NMDA receptor gates two inhibitory sites for zinc, one is voltage dependent and the other is not. The γ-amino butyric acid released from striatal slices is calcium-independent. Calcium channels may play two roles in the regulation of depolarization-induced GABA release. First, they permit depolarization-induced influx of calcium, which then promotes GABA release. Second, they influence GABA release through a mechanism that does not involve external calcium. It has been proposed that calcium channels serve to permit an influx of Na⁺, which in turn promotes calcium-independent GABA release through an influence on the high affinity GABA transport system. Blockage of choline uptake may play a role in the antidepressant-like effect of verapamil.

Alprazolam may produce antidepressant effects independently of benzodiazepine receptors, through the GABA-ergic mechanism. Flumazenil did not antagonize the antidepressant effects of alprazolam or imipramine, while these effects were blocked by picrotoxin. Enhanced 5-HT release in the hippocampus, exhibited by the typical benzodiazepine, alprazolam, but not by the typical benzodiazepine, diazepam, may underlie the antidepressant activity of alprazolam. It has been suggested that some of the neuronal stabilizing effects of benzodiazepine receptors may be mediated by the regulation of Ca²⁺ conductance, as benzodiazepine binding sites regulate voltage-sensitive Ca²⁺ channels in brain membranes. Benzodiazepines and calcium channel inhibitors cause significant inhibition of adenosine transport; hence, this potentiates adenosine action at the concentration required to induce effects through occupation of their respective, specific high-affinity sites. Benzodiazepine (clonazepam, flunitrazepam, and diazepam) binding sites regulate voltage-sensitive Ca²⁺ channels in brain membranes, and it has been suggested that some of the neuronal stabilizing effects of benzodiazepine receptors may be mediated by the regulation of Ca²⁺ conductance. Diazepam had no effect on the immobility time in the swimming maze, but antagonized the antidepressant effect of imipramine. This means that both alprazolam and imipramine produce antidepressant effects through voltage-sensitive Ca²⁺ channels. Benzodiazepines act as Ca²⁺-channel antagonists; this antagonism may not be related to their antidepressant action.

Imipramine can inhibit presynaptic reuptake of the biogenic amines, serotonin, and NA to produce an antidepressant effect. Imipramine may produce this antidepressant action through a GABA-ergic mechanism, causing release of catecholamines. Imipramine may increase calcium release from intracellular stores by increasing NA concentrations through inhibiting its uptake by pre-synaptic sites, through GABAA receptor activation.
lead to increased calcium influx through voltage-gated calcium channels, which ultimately depend on the chloride transport system [91], or by depolarization due to an increase in the external potassium concentrations. It was suspected that this might lead to calcium influx through voltage-activated calcium channels [92]. However, nifedipine does not affect calcium channel mediation of initial response to NA [93]. Nifedipine blocks L-type calcium channels activation which is due GABAA receptor activation-mediated depolarization [94, 95], which may not play a role in the antidepressant action. GABAA receptor activation increases the release of calcium from the internal stores [95]. Imipramine produces an inhibition of the peak threshold calcium current, which probably decreases the maximum available calcium conductance [96]. It was suggested that imipramine acts by interfering with the influx of extracellular calcium, through both the receptor-operated and voltage-gated calcium channels, but does not affect the release of calcium from intracellular storage sites [97, 98].

In the present study we showed that verapamil has an antidepressant-like effect in the mouse swimming maze model. Treatment with verapamil combined with alprazolam or imipramine produces an additive antidepressant effect, possibly because verapamil has an antidepressant-like effect, but the mechanism is not understood yet.

Either imipramine or nifedipine produced a delay in the onset of immobility of 75% and 81%, respectively, compared to the control. Combining nifedipine with imipramine led to a delay of 73% in the onset of immobility compared to the control; which is less than the additive effect. This observation could be explained by the fact that nifedipine has its own antidepressant action mechanism but also blocks the imipramine mechanism that depends on L-type calcium channel activation.

This study showed that nifedipine possesses antidepressant properties. Combining nifedipine with alprazolam produced an additive antidepressant effect, indicating that different mechanisms were involved.

References
1. Rang MM, Dale JM, Ritter. Pharmacology. CNS stimulants and psychomimetic drugs 1996; Third edition. Laurence Hunter, New York, London. Chapter four. P:634.
2. Hascoet M, Bourin M. Anti-conflict effect of alpidedm as compared with the benzodiazepine alprazolam in rats. Pharmacol. Biochem. Behav. 1997;59(2): 317 – 324.
3. Reynolds JEF, Partiti K, Parson AV, Sweetman SC. The imipramine. In: Martindale. The extra pharmacopoeia. Royal pharmaceutical society. 1996; Thirty-first edition, 316– 317.
4. Baldessarini JR. Drugs and treatment of psychiatric disorders (depression and mania). In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics1996; 9th edition. McGraw-Hill, New York. Chapter 19, p 431.
5. Pin JP, Bockaert J. Omega-conotoxin GVIA and dihydropyridines discriminate two types of Ca2+ channels involved in GABA release from striatal neurons in culture. Eur J. Pharmacol. 1990; 188: 81-84.
6. Kozlovskaí VL, Prakhe IV. The influence of calcium channel blockers on antidepressant effects Eksp Klin Farmakol. 1996; 59(5): 9-11.
7. Mathys M. Drug Interactions Associated with the Use of Antidepressant Medications. Internet Continuing Education 2005; 9(3) 1-15.
8. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002;19(4):299-320.
9. Porsolt RD, Lepichon M, Jaffra M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266:730-732.
10. Porsolt RD, and Lenegre A. Behavioural models of depression. Experimental approaches to anxiety and depression 1992; 5:73-84.
11. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 1988; 94: 147-160.
12. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent development and future needs. Trends in Pharmacological Sciences 2002; 23(5): 238-245.
13. Jaarunus H. Animal Models for Better Antidepressants: Can Pathogenetic Approaches Make a Difference? Review 2004; 2(6): 402-407.
14. Willner P. The validity of the animal models of depression. Psychopharmacology 1984; 83:1-16.
15. Raghavendra V, Kaur G, Kulkarni SK. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychopharmacol 2000; 10(6):473-481.
16. Bournin M, Fiocco AJ, Clenet F. How valuable are animal models in defining antidepressant activity? Hum. Psychopharmacol. Clin. Exp. 2001; 16:9-14.
17. Collinge J, Pycock CJ, Taberner PV. Studies, on the interaction between cerebral 5- Hydroxy tryptamine and 6- amino butyric acid in the mode of action of Diazepam in the rat. Br. J. Pharmac 1983; 79:637–643.
18. Biaga G. Antidepressant-like properties of some serotonin receptor ligands and calcium channel antagonists measured with the forced swimming test in mice. Polish Journal of Pharmacology. 1998; 50(2):117-124.
19. Ali A, Pillai KK, Pal SN, Ahmad FJ, Vohora D. Addition of folic acid to phenytoin ameliorates neuropharmacological complications in mice. Asia Pacific Journal of Pharmacology. 2004; 16(2):83-88.
20. Szymczyk G, Zebrowska-Lupina I. Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Polish Journal of Pharmacology. 2000; 52(5):337-344.
21. Volterra G, Lecce A. Interaction of antidepressants with 4-aminopyrindine. Life Sciences. 1992; 51(6):PL53-PL56.
22. Porsolt RD. Behavioral despair. In: neurochemical., behavioral and clinical persp espective. (edit: Enna, S.J.; Malick, J. P., Richelson, e.). Reven Press, New York 1981; 121–139.
23. Porsolt RD, Bertin A, Jafer M. Behavioral despair in rats and mice: Strain differences and the effect of imipramine. Eur. Pharmacol 1978; 51:291-294.
24. Abel EL. A further analysis of physiological changes in rats in the forced swim test. Physiol Behav 1994; 56(4):795-800.
25. Helmeста DM, Tang SW. The role of calcium in the etiology of the affective disorders. Japanese Journal of Pharmacology 1998; 77(2):107-116.

Libyan J Med, AOP: 070909
26. Paul IA. Antidepressant activity and calcium signaling cascades. Human Psychopharmacology 2001; 16(1):71-80
27. Rehavi M, Carmi R, Weizman A. Tricyclic antidepressants and calcium channel blockers: Interactions at the (-)-desmethoxyverapamil binding site and the serotonin transporter. Eur. J. Pharmacol. 1998; 352(1):25-30.
28. Geoffroy M, Mogilnica E, Nielsen M, Rafaelsen OJ. Effect of nifedipine on the shuttlebox escape deficit induced by inescapable shock in the rat. Eur. J. Pharmacol. 1988; 153(3):275-283.
29. Bayliss DA, Umemiya M, Berger AJ. Inhibition of N- and P-type calcium currents and the after-hyperpolarization in rat motoneurons by serotonin. J Physiol 1995; 485(3):635-647.
30. Ladewig T, Laalley PM, Keller BU. Serotonergic modulation of intracellular calcium dynamics in neonatal hypoglossal motoneurons from mouse. Brain Res. 2004; 1001(1-2):1-12.
31. Reiser G, Donie B, Binnmoller FJ. Serotonin regulates cytosolic Ca2+ activity and membrane potential in a neuronal and in a glial cell line via 5-HT3 and 5-HT2 receptors by different mechanisms. J. Cell Sci. 1989; 93(3):545-555.
32. Buriy VA, Gurkovskaya AV, Gokina NI, Shuba MF. Effects of the membrane potential level on serotonin-induced contraction of the pulmonary artery smooth muscle in rabbits. Biull. Eksp. Biol. Med. 1992; 113(1):13-16.
33. Linhart O, Obreja O, Kress M. The inflammatory mediators serotonin, prosta glandin E2 and bradykinin evoke calcium influx in rat sensory neurons. Neuroscience 2003; 118(1):69-74.
34. Løvinger DM. 5-HT3 receptors and the neural actions of alcoholic: an increasingly exciting topic. Neurochem. Int. 1999; 35(2):125-130.
35. Rammes G, Rupprecht R, Ferrari U, Ziegglansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and NIE-115 cell systems in a non-competitive manner. Neurosci. Lett 2001; 306(1-2):81-84.
36. Okoro EO. Overlap in the Pharmacology of L-type Ca2+-channel Blockers and 5-HT, Receptor Antagonists in Rat Aorta. Journal of Pharmacy and Pharmacology 1999; 51(8):953-957.
37. Das P, Boll-Honer CL, Huang RQ, Raut A, Gonzales EB, Chen ZL, et al. Inhibition of type A GABA receptors by L-type calcium channel blockers. Neuroscience 2004; 124(1):195-206.
38. Katooka Y, Ohara-Imaizumi M, Ueki S, Kumakura K. Stimulatory action of gamma-amino-butyric acid on catecholamine secretion from bovine adrenal chromaffin cells measured by a real-time monitoring system. J. Neurochem 1988; 50(6):1765-1768.
39. Leppert J, Nilsson H, Myrdal U, Edvinsson L, Hedner T, Ringqvist I. Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud’s patients and controls. Cardiovasc. Drugs Ther 1993; 7(6):901-907.
40. Khojai MA, Dalziel HH, Zhang L, Bjur RA, Gerthoffer WT, Buxton IL, et al. [Ca2+]i-sensitive, IP3-independent Ca2+ influx in smooth muscle of rat vas deferens revealed by procaine. Br. J. Pharmacol. 1993; 110(4):1353-1358.
41. Terlinden O. Catecholamine release–unpredictable side effects of calcium antagonists. Tidskr Nar Lægeforen 1992; 112(15):1952-1954.
42. Wendling WW, Hakal C. Effects of calcium antagonists on isolated bovine cerebral arteries: inhibition of constriction and calcium-45 uptake induced by potassium or serotonin. Stroke 1987; 18(3):591-598.
43. Nalepa I, Kowalska M, Kreiner G, Vetulani J. Does Ca2+ channel blockade modulate the antidepressant-induced changes in mechanisms of adrenergic transduction? J. Neural. Transm. 1997; 104(4-5):535-547.
44. Hoste AM, Sys SU. The relaxant action of betaxolol on isolated bovine retinal microarteries. Curr. Eye Res. 1994; 13(7):483-487.
45. Andersson KE. Pharmacodynamic profiles of different calcium channel blockers. Acta. Pharmacol. Toxicol. 1986; 58(2):31-42.
46. Galzin AM, Langer SZ. Presynaptic alpha 2-adrenergic antagonist by verapamil but not by diltiazem in rabbit hypothalamic slices. Br. J. Pharmacol. 1983; 78(3):571-577.
47. Turovaya AY, Galenko-Yaroshvskii PA, Kade,AKh, Uvarov AE, Kiguradze MI, Khvitiya NG, et al. Effects of verapamil and amidadrone on sympathoadrenal system and balance of excitatory and inhibitory amino acids in rat medulla oblongata. Bull. Exp. Biol. Med. 2005; 139(6):665-667.
48. Kudrin VS, Klotd PM, Gulieva ST. Neuropharmacological study of the joint action of verapamil and olanzapine on the content of neurotransmitters in Wistar rat brain structures. Eksp. Klin. Farmakol. 2005; 68(6):12-14.
49. Oriowo MA. Differential effect of verapamil on noradrenaline, carbachol, tyramine and 5-hydroxytryptamine induced contractions of the rat anococcygeus muscle. Arch. Int. Pharmacodyn. Ther. 1992; 259(2):186-33.
50. Raviprakash V, Mishra SK, Panda JN. Effect of verapamil on the non-adrenergic response of the field stimulated rat vas deferens. Naunyn. Schmiedebergs. Arch. Pharmacol. 1985; 331(4):347-350.
51. French AM, Scott NC. Evidence to support the hypothesis that ATP is a co-transmitter in rat vas deferens. Experientia. 1983; 39(3):264-266.
52. Garner C, Fenikw W, Brown PD. Serotonin activates Cl-channels in the apical membrane of rat choroid plexus epithelial cells. Eur. J. Pharmacol. 1993; 239(1-3):31-37.
53. Clemens Allgayer, Thomas Henning Weilmann, Angelika Schobert, Gerhart Kurz and Ivar von Kügelgen. Cultured chick sympathetic neurons: ATP-induced noradrenaline release and its blockade by nicotinic receptor antagonists. Naunyn-Schmiedeberg’s Archives of Pharmacology 1995; 352(1):25-30.
54. Gurkovskaya AV. Effect of manganese and verapamil on electrical and contractile responses of pulmonary artery smooth muscle induced by noradrenaline and histamine. Biull. Eksp. Biol Med 1981; 92(8):7-9.
55. Criddle DN, de-Moura RS, Greenwood IA, Large WA. Effect of nifedipine acid on noradrenaline-induced contractions of the rat aorta. Br. J. Pharmacol. 1996; 118(4):1065-1071.
56. Hill NS, Lee SL, Fanburg BL. Effect of calcium channel blockers on serotonin uptake. Proc. Soc. Exp. Biol. Med 1990; 193(4):326-330.
57. Pietraszek M, Chabielka E, Malinowska B, Buzzcko W. The effect of verapamil on serotoninergic mechanisms in the rat blood platelets. Pol. J. Pharmacol. Pharm. 1988; 40(1):81-86.
58. Lee SL, Long K, Ueda S, Fanburg BL. Verapamil inhibits serotonin uptake of endothelial cells in culture by a mechanism unrelated to Ca2+- channel blockade. J. Cell. Physiol. 1987; 132(1):178-182.
59. Brown NL, Sirugue O, Woric M. The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur. J. Pharmacol. 1986; 123(1):161-165.
60. Sitges M, Reyes A. Effects of verapamil on the release of different neurotransmitters. J. Neurosci. Res. 1995; 40(5):613-621.
61. Biela G. Antidepressant-like properties of some serotonin receptor ligands and calcium channel antagonists measured with the forced swimming test in mice. Pol. J. Pharmacol. 1998; 50(2):117-124.
62. Ronde P, Nichols RA. High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum. J. Neurochem. 1996; 70(3):1084-1103.
63. Ronde P, Nichols RA. 5-HT3 receptors induce rises in cytosolic and nuclear calcium in NG108-15 cells via calcium- induced calcium release. Cell Calcium 1997; 22(5):357-365.
64. Morales M, Bloom FE. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J. Neurosci. 1997; 17(9):3157-3167.

65. Garner C, Feniuk W, Brown PD. Serotoninotin activates CI-channels in the apical membrane of rat choroid plexus epithelial cell. Eur. J. Pharmacol. 1993; 239(1-3):31-37.

66. Declan WA, Stefano C, Pierre D. Ionotropic and metabotropic activation of a neuronal chloride channel by serotonin and dopamine in the leech Hirudo medicinalis. The Journal of Physiology 1998; 509(1):211-219.

67. Carmines PK. Segment-specific effect of chloride channel blockade on rat renal arteriolar contractile responses to angiotensin II. Am J Hypertens 1995; 8:90–94.

68. Takenaka T, Kanno Y, Kitamura Y, Hayashi K, Suzuki H, and Saruta T. Role of chloride channels in afferent arteriolar constriction. Kidney Int. 1996; 50:864–872.

69. Baron A, Pacaud P, Loirand G, Mironneau C, Mironneau J. Pharmacological block of Ca(2+)-activated Cl- current in rat vascular smooth muscle cells in short-term primary culture. Pflugers Arch. 1991; 419(6):553-558.

70. Pacaud P, Loirand G, Baron A, Mironneau C, Mironneau J. Ca(2+)-channel activation and membrane depolarization mediated by Cl-channels in response to noradrenaline in vascular myocytes. Br. J. Pharmacol. 1991; 104(4):1000-1006.

71. Jensen BL, Ellekviest P, Skott O. Chloride is essential for contraction of afferent arterioles after agonists and potassium. Am J Physiol. 1990; 328:640-643.

72. Nishida A, Hayashi T, Motohashi N, Yamawaki S. gamma-Aminobutyric acid increases intracellular Ca2+ concentration in cultured cortical neurons: role of Cl-channel activati on and membrane depolarization. Pflugers Arch. 1991; 419(6):553-558.

73. Takenaka T, Kanno Y, Kitamura Y, Hayashi K, Suzuki H, and Saruta T. Role of chloride channels in afferent arteriolar constriction. Kidney Int. 1996; 50:864–872.

74. Christine CW, Choi DW. Effect of zinc on NMDA receptor-mediated channel currents in cortical neurons. J. Neurosci. 1990; 10:108-116.

75. Peters S, Koh J, Choi DW. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science 1987; 236:589-593.

76. Westbrook GL, Mayer ML. Micromolar concentrations of Zn2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature1987; 328:640-643.

77. Berrnth S, Zigmond MJ. Calcium-independent GABA release from striatal slices: the role of calcium channels. Brain Res. 1990; 534(1-2):51-59.

78. Takeda A, Minami A, Seki Y, Oku N. Differential effects of zinc on glutamatergic and GABAergic neurotransmitter systems in the hippocampus. J. Neurosci. Res. 2004; 75(2):225-229.

79. Shing O, Cheung E, Leung D, et al. Effect of imipramine on calcium utilization of single detrusor muscle in relation to calcium modulation. Korean Journal of Pharmacology 1992; 28(3):677-682.

80. Broderick PA, Alprazolam, diazepam, yohimbine, and imipramine affect the release of calcium from the sarcoplasmic reticulum of canine vascular smooth muscle cells isolated from canine detrusor. Eur. J. Pharmacol. 1983; 87(4):367-378.

81. Delpon E, Tamargo J, Sanchez Chapula J. Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes. Naunyn Schmiedeberg's Archives of Pharmacology 1991; 344(6):645-652.

82. Lee JB, You KJ, Ha JH, Kwon OC, Lee KY, Kim WJ. Mechanism of inhibitory effect of imipramine on isolated rat detrusor muscle in relation to calcium modulation. Korean Journal of Pharmacology 1992; 28(1):81-89.

83. Shim HS, Choi HC, Jeong YS, Kim JH, Lee KY, Sohn UD, et al. Effect of imipramine on calcium utilization of single cells isolated from canine detrusor. Korean Journal of Physiology and Pharmacology 1999; 3(4):439-445.